One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
- :
Price : 100$- Special Price : 50$
Overcoming Barriers to Make Patient-Reported Outcome Collection the Standard of Care in Oncology.
New CMS Illness Navigation Codes: LinchPIN to Ensuring Better Access to Care?.
Nontransplant Treatment for Relapsed Pediatric Hodgkin Lymphoma-Less Is More.
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults: A Nonrandomized Clinical Trial.
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX.
Intratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial.
Genetic Ancestry-Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies.
Molecular Testing for the World Health Organization Classification of Central Nervous System Tumors: A Review.
Biomarker-Directed Radiotherapy in Breast Cancer: A Narrative Review.
Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial.
Weight Changes and Heart Failure Risk After Breast Cancer Development.
Gastroenteropancreatic Neuroendocrine Tumor Incidence by Sex and Age in the US.
Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti-PD-1 Therapy.
Concerns in Interpretation of Results in the Identification of Immune Checkpoint Inhibitor-Induced Diabetes.
Concerns in Interpretation of Results In the Identification of Immune Checkpoint Inhibitor-Induced Diabetes-Reply.
